Cabozantinib, a tyrosine kinase inhibitor (TKI), was recently approved for patients with previously treated pancreatic NETs.

A new study reveals that small cell lung cancer (SCLC) likely begins in basal stem-like cells rather than in neuroendocrine ...

Exelixis (EXEL) stock wins a Buy at Goldman Sachs based on potential of its lead asset, zanzalintinib, ahead of a patent ...

Findings from a new study by Duke researchers are shifting the way one of the deadliest forms of lung cancer is understood and offering fresh insights that could revolutionize treatment approaches.

A new study reveals that small cell lung cancer (SCLC) likely begins in basal stem-like cells rather than in neuroendocrine cells ...

Hair and blood biomarkers may predict mental health risks in children with chronic illness and stress-related hair loss, ...